http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020143042-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_850a17186ff51f03c607cf42a534a635
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4468
filingDate 2020-01-16^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cd186a7d8492a89817b2b270b2b0eb7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bd4fffc54a7b5f829772ce39a20db8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7304477cefe04f0d9665360e710d4513
publicationDate 2020-09-10^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2020143042-A
titleOfInvention Transdermal preparation
abstract PROBLEM TO BE SOLVED: To provide a fentanyl-containing transdermal preparation capable of reducing a decrease in analgesic effect occurring on the third day after application. According to the present invention, a support, a drug-containing layer laminated on the support, a drug control membrane laminated on the drug-containing layer and permeable to the drug, and a drug control membrane. In a transdermal formulation having a laminated adhesive layer, The drug-containing layer comprises a pressure-sensitive adhesive and drug-containing particles containing fentanyl or a pharmaceutically acceptable salt thereof and a solubilizer dispersed in the pressure-sensitive adhesive. When the transdermal preparation is applied to the skin for 72 hours, the time elapsed from the application of the transdermal preparation is 48 to 72 hours in the blood of fentanyl or a pharmaceutically acceptable salt thereof. concentration not less than 0.2 ng / mL, the coefficient of variation of AUC 48-72 of fentanyl or a pharmaceutically acceptable salt thereof to provide a percutaneous preparation 35% or less. [Selection diagram] Fig. 1
priorityDate 2019-02-28^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008517934-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005501865-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2000044476-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005526839-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018221297-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S6137725-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004202704-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID178
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415730545
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1443
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419603572
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419521001
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID916
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID14
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62427
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507675
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419489467
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3345
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID168350
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419521658
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7758
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8179
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID376
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451051385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419476272
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15505
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7528

Showing number of triples: 1 to 42 of 42.